Low rates of adverse cutaneous effects seen with successful, appropriate life-saving shocks
By Lori Solomon HealthDay Reporter
FRIDAY, Aug. 2, 2024 (HealthDay News) — A novel, water-resistant patch-wearable cardioverter-defibrillator (P-WCD) is safe and effective for patients at risk for sudden cardiac arrest, according to a study published in the Aug. 6 issue of the Journal of the American College of Cardiology.
John Hummel, M.D., from The Ohio State University in Columbus, and colleagues assessed the safety and clinical effectiveness of a novel P-WCD. The analysis included 290 patients at risk for sudden cardiac arrest due to ventricular tachycardia/ventricular fibrillation who were not candidates for or refused an implantable defibrillator.
The researchers found that the clinically significant cutaneous adverse device effect rate was 2.30 percent, with no severe adverse effects. There were no device-related deaths or serious adverse events reported. The inappropriate shock rate was 0.36 per 100 patient-months. Nine patients received 11 shocks, of which nine shocks were adjudicated to be appropriate. Eight of nine appropriate shocks were successful with a single shock. Median wear time compliance was 23.5 hours per day.
“There were no patient deaths or missed episodes requiring external rescue, and high patient compliance enabled a high number of successful life-saving conversions,” the authors write.
Several authors disclosed ties to medical device companies, including Element Science, which manufactures the studied P-WCD and funded the trial.
Editorial (subscription or payment may be required)
Copyright © 2024 HealthDay. All rights reserved.
